Andrew King was named President of Jade Biosciences, Inc., effective April 18, 2026. As of November 6, 2026, Jade Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 22, 2026 to June 26, 2026, naming 2 appointments (Form 8-K, April 22, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Jade Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Jade Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-22 to 2026-06-26. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Jade Biosciences, Inc. files it.
Also on the record for Jade Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G, by Franklin Templeton, Inc. | 6% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Bellevue Group AG | 5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 8.3% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.1% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 10.6% of the class | 5%+ stakes | Source |
| June 9, 2026 | Stake report, Schedule 13D/A, by Fairmount Funds Management LLC | 19.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 6.3% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.7% of the class | 5%+ stakes | Source |
| March 5, 2026 | Stake report, Schedule 13D/A, by Sofinnova Venture Partners X, L.P. ("SVP X") | 0.3% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Bellevue Group AG | 6.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by JANUS HENDERSON GROUP PLC | 6.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Jade Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Jade Biosciences, Inc. and the records around it.
Jade Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Vera Therapeutics, Inc. (Mar 2026)
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Celldex Therapeutics, Inc. (May 2026), Viridian Therapeutics, Inc. (May 2026)
- Fairmount Funds Management LLC also filed stake reports on 13 other companies: Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026), Korsana Biosciences, Inc. (Sep 2026)
Watch Jade Biosciences, Inc.
Get an email when Jade Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jade Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Jade Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jade Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-26 | In | 8-K, 2026-06-26 | |||
| 2026-04-22 | In | President | 2026-04-18 | 8-K, 2026-04-22 |
Who leads Jade Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Andrew King, appointed, effective 2026-04-18 (filed 2026-04-22).
New leaders reset buying decisions — get the Full Report on Jade Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at Jade Biosciences, Inc., with the record behind each one.
Find candidates like President at Jade Biosciences, Inc.Every change, in the filing's words
Appointed: Mark Eisner
The Board also appointed Dr. Eisner to serve as a member of the Nominating and Corporate Governance Committee of the Board.
- On June 25, 2026, the Board of Directors (the "Board") of Jade Biosciences, Inc. (the "Company") appointed Mark Eisner, M.D., M.P.H., to serve as a Class I director of the Company, to hold office until the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation, death or removal.
- Dr. Eisner most recently served as Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (Nasdaq: VIR) from June 2024 to April 2026, where he oversaw clinical development, regulatory sciences, and medical affairs.
- Previously, he served as Chief Medical Officer at Sonoma Biotherapeutics, Inc., a private clinical-stage biotechnology company, from September 2023 to June 2024.
- From 2020 to September 2023, he served as Executive Vice President, Chief Medical Officer at FibroGen, Inc. (now known as Kyntra Bio, Inc.) (Nasdaq: KYNB), a biopharmaceutical company.
- Prior to FibroGen, Dr. Eisner spent nearly 11 years at Genentech, Inc., a member of the Roche Group, including as Senior Vice President, Global Head of Product Development Immunology, Infectious Disease and Ophthalmology from 2018 to 2020.
- Prior to entering industry, Dr. Eisner was Professor of Medicine and Anesthesia at the University of California, San Francisco.
Appointed: Andrew King, President, effective 2026-04-18
On April 18, 2026, the Board of Directors of Jade Biosciences, Inc. (the "Company") appointed Andrew King, BVMS, Ph.D. as the Company's President, Research & Development, effective as of April 18, 2026.
- Dr. King was previously the Company's Chief Scientific Officer and Head of Research & Development.
- No changes were made to Dr. King's compensation in connection with such appointment.
Tools for this story
Each opens in a new tab, filled in for Jade Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.